BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Graft-versus-host disease clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for graft vs host disease: 62 (42 sponsors; 8 newly posted in the last 180 days, 5 stopped in the last 180 days; 4 new-entrant sponsors). Momentum score 8.9, rank 78 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 2, Phase 1 7, Phase 2 24, Phase 3 13, Phase 4 6, N/A 10.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Incyte Corporation INCY7NA 1, P3 3, P2 301
Sanofi SNY5P2 1, P4 1, P3 2, P1 121
Dompé Farmaceutici S.p.A2P3 201
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.3P2 2, P3 100
medac GmbH2P2 1, P3 100
Regenerative Ocular Immunobiologics LLC2P3 1, P2 112
Incyte Biosciences Japan GK INCY1P3 100
Janssen Research & Development, LLC1P3 101
Mesoblast, Ltd. MESO1P3 100
Novartis Pharmaceuticals NVS5P2 1, NA 1, P4 300
Ausper Biopharma Co., Ltd. new entrant2P1 1, P2 120
Abbisko Therapeutics Co, Ltd1P2 100
Beijing Tide Pharmaceutical Co., Ltd1P2 100
Bellicum Pharmaceuticals1P2 100
Biokosmes Srl1NA 100
BioPhoenix Co., Ltd.1P2 100
Cellenkos, Inc.1P2 100
Cision Vision, Inc. new entrant1NA 110
Curonix LLC1NA 100
Daewoong Pharmaceutical Co. LTD.1NA 100
Deciphera Pharmaceuticals, LLC1P2 100
Dr. Reddy's Laboratories Limited, India new entrant1P1 111
Enterra Medical, Inc.1NA 100
Grand Theravac Life Sciences (Hangzhou) Co., Ltd. new entrant1P2 110
Grit Biotechnology1EARLY_P1 100

New-entrant sponsors: Ausper Biopharma Co., Ltd., Cision Vision, Inc., Dr. Reddy's Laboratories Limited, India, Grand Theravac Life Sciences (Hangzhou) Co., Ltd..

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2ReAlta Life Sciences, Inc.NCT06343792 Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host DiseaseSteroid Refractory GVHDrecruiting66
2026-12 est.P1/P2Wuhan Optics Valley Vcanbiopharma Co., Ltd.NCT06677255 A Phase I/II Trial of VUM02 Injection for Steroid-refractory Acute Graft-versus-host Disease (SR-aGvHD) TreatmentSteroid-refractory Acute Graft-versus-host Diseasenot yet recruiting149
2026-12-31 est.P3Janssen Research & Development, LLCNCT01804686 A Long-term Extension Study of PCI-32765 (Ibrutinib)Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma;active not recruiting539
2027-01-06 est.P1/P2Incyte Corporation INCYNCT06843408 A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHDChronic Graft-versus-host-diseaseactive not recruiting32

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-30 est.P1/P2Nuwacell Biotechnologies Co., Ltd.NCT06941350 A Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHDAcute Graft-versus-Host Diseasenot yet recruiting24
2026-10-01P2Incyte Corporation INCYNCT06388564 A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host DiseaseChronic Graft-versus-host-diseaseactive not recruiting130
2026-08-31 est.P2Kadmon, a Sanofi CompanyNCT05567406 Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and FChronic Graft Versus Host Diseasewithdrawn

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "graft vs host disease"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.